Neurotech Investor Roadshow 2016, page-21

@nichols Sorry that calculation is done taking all the other costs mentioned in the investor presentation in as well... So it's far more than 2.5x PE... But I also agree with you that an early stage Biotech would be much higher so I am defo being conservative!
But as per @Pixie2000 question, and my previous one... I think it's far more important we are accurate on pricing numbers (facts) before deciding what multiple it should trade on! (Wizardry!)

RRP of mente2 = 1700...... & Cost? Distributor margin 30%?

RRP of mente autism = not quoted in presentation...... & Cost?

Profit per unit to NTI of Mente autism?

Then we have addition revenue 1 year after sale of €99 per unit per year for subscription?

Sorry to be dull, but my background is 12 years of building models around valuations... And this is impossible without accurate pricing. And this company looks very very interesting for a major investment if I can get the model looking accurate. And I couldn't make it to the roadshow unfortunately as live in London.